secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K
Filed at:   2022-07-29T23:59:59+00:00
Accession:  0001628280-22-019768
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07
------------------------------------------------------------------------------

- Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).
- Adjusted EBITDA $56.5M, up 12.6% YoY; all three segments posted sales growth.
- Completed acquisition of Kappa (vitamin K2 manufacturer) on June 21, 2022; expands nutrition portfolio.
- Entered new $550M revolving credit facility due 2027, replacing $500M facility due 2023.
- Cash from operations $48.2M; net debt $357.4M, leverage ratio 1.8x.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/0001628280-22-019768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000162828022019768/bcpc-20220729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-019768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer